Authors: Shawver, LK Lipson, KE Fong, TAT McMahon, G Strawn, LM

Citation: Lk. Shawver et al., Receptor tyrosine kinases in angiogenesis, NEW ANGIOTHERAPY, 2002, pp. 409-452

Authors: Sonnenfeld, G Tovey, M Schellekens, H Kinney, KS Belay, T Morton, DS Austin, CE Reitman, M Fong, TAT Vaughan, HS

Citation: G. Sonnenfeld et al., Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murineencephalomyocarditis virus, J INTERF CY, 21(7), 2001, pp. 539-545

Authors: Vajkoczy, P Menger, MD Goldbrunner, R Ge, SG Fong, TAT Vollmar, B Schilling, L Ullrich, A Hirth, KP Tonn, JC Schmiedek, P Rempel, SA

Citation: P. Vajkoczy et al., Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC, INT J CANC, 87(2), 2000, pp. 261-268

Authors: Laird, AD Vajkoczy, P Shawver, LK Thurnher, A Liang, C Mohammadi, M Schlessinger, J Ullrich, A Hubbard, SR Blake, RA Fong, TAT Strawn, LM Sun, L Tang, C Hawtin, R Tang, F Shenoy, N Hirth, KP McMahon, G Cherrington, JM

Citation: Ad. Laird et al., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors, CANCER RES, 60(15), 2000, pp. 4152-4160

Authors: Fong, TAT Shawver, LK Sun, L Tang, C App, H Powell, TJ Kim, YH Schreck, R Wang, XY Risau, W Ullrich, A Hirth, KP McMahon, G

Citation: Tat. Fong et al., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, CANCER RES, 59(1), 1999, pp. 99-106